Viksnins Harris Padys Malen LLP
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
ARDELYX, INC.
A A C A A A A A A A A A A A A Y A C A A A C
A61K A61P C07D A61K A61K A61K A61P A61P A61K A61P A61P A61K A61K A61P A61P Y02A A61P C07D A61K A61K A61P C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional
Christopher Dominique Tao Jason Jeffrey Michael Noah
Carreras Charmot Chen Lewis Jacobs Leadbetter Bell